ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

DePinho Explains Tenure Decision,Professors Dispute Key Details

May 30, 2014

USLA’’s Steckel Asks More Centers Staff, Strict Enforcement of Guidelines

February 17, 1978

Letter: ORI And Plotkin Should Release Report

June 23, 1995

DSMB Recommends Discontinuing Phase III Perifosine Combination Trial

March 29, 2013

NCAB Approves Year 2000 Report; Implementation Depends On Adequate Funding Starting With FY 1986

July 12, 1985

New Tests Rule Out Theory On Polio Vaccine-AIDS Link.

October 6, 2000